Cleveland Biolabs, Inc. (CBLI) Posts In-Line Q1 Loss of 15c/Share

Cleveland Biolabs, Inc. (NASDAQ: CBLI) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $931 thousand versus the consensus estimate of $3.5 million.

For earnings history and earnings-related data on Cleveland Biolabs, Inc. (CBLI) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• zSpace, Inc. (ZSPC) Reports Q2 results
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c